In this video, Professor David Lanfear (Henry Ford Hospital, Detroit, MI, US) discusses a subgroup analysis of GALACTIC-HF which aimed to evaluate the effect of omecamtiv mecarbil in black patients with heart failure (HF) with reduced ejection fraction (HFrEF). Originally presented at HFSA 2021, the additional results suggest that the outcomes in black patients treated with this drug are similar to those in the overall population of the trial and white patients, showing the drug is effective and safe to use across ethnic groups.
Importance of this subgroup analysis
Study design and patient population
Impact on practice and further research
Recorded Remotely from Detroit, 2021.
Interviewer: Jordan Rance